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The Factor V Leiden (FVL) mutation is the commonest thrombotic risk factor in 
humans. Heterozygous carriers have an approximately 10% lifetime incidence of 
venous thrombosis, compared to 80% in homozygotes. FVL is resistant to 
degradation by Activated Protein C (APC), resulting in prolonged factor V (FV) 
prothrombinase cofactor activity. In vitro studies suggest that FV can serve as a 
cofactor for APC in the inactivation of Factor VIIIa, with FVL demonstrating a 
reduced cofactor activity. To address the relative in vivo contributions of these 
mechanisms to thrombosis associated with FVL, we examined crosses among 
genetically engineered mice heterozygous deficient for FV (Fv+/-) or tissue factor 
pathway inhibitor (TFPI, Tfpi+/-), homozygous or heterozygous for the FVL 
mutation (FvQ/Q or FvQ/+), or carrying either a liver specific (MalbFvTg+) or 
platelet specific (Pf4FvTg+) FV transgene. Analysis of offspring from an intercross 
between FvQ/- and FvQ/Q mice demonstrated a reduction in the survival of FvQ/- 
mice compared to FvQ/Q (49 vs. 113 out of 162 total offspring, expected ratio is 
1 : 1, p < 0.05). We recently reported synthetic thrombotic lethality of the FvQ/Q 
and Tfpi+/- genotypes. Analysis of FvQ/- mice in the setting of reduced TFPI 
demonstrated a similar uniform lethality for the FvQ/- Tfpi+/- genotype, in contrast 
to the normal survival of FvQ/+Tfpi+/- mice. Introduction of either the MalbFv or 
Pf4Fv transgenes into this cross resulted in partial rescue of the lethal FvQ/- Tfpi+/- 
phenotype. These data confirm the association of homozygous FVL with a more 
severe thrombotic phenotype than in heterozygotes. These findings identify the 
critical mechanism for this enhanced thrombosis as loss of a wild-type-specific 
activity, rather than increased APC resistance. This critical wild type FV function can 
be provided by either the platelet or plasma FV pool. These findings have important 
implications for the role of FV in the regulation of hemostatic balance.
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